bioRxivBiochemistry
Targeting the Pregnane X Receptor Using Microbial Metabolite Mimicry
Z. Dvorak, F. Felix Kopp, C. M. Costello, J. S. Kemp, H. Li, A. Vrzalova, M. Stepankova, I. Iveta Bartonkov, K. Poulikova, B. Vyhlidalova, L. U. Nordstroem, C. Karunaratne, H. Ranhotra, K. S. Mun, A. P. Naren, I. Murray, G. H. Perdew, J. Brtko, L. Toporova, A. Schon, B. Wallace, W. G. Walton, M. R. Redinbo, K. Sun, A. Beck, , R. B. Sartor
Abstract
The human pregnane X receptor (PXR), a master regulator of drug metabolism, has important roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off-target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows to exploit previously unexplored parts of chemical space. Here we report functionalized indole-derivatives as first-in-class non-cytotoxic PXR agonists, as a proof-of-concept for microbial metabolite mimicry. The lead compound, FKK6, binds directly to PXR protein in solution, induces PXR specific target gene expression in, cells, human organoids, and mice. FKK6 significantly represses pro-inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The development of FKK6 demonstrates for the first time that microbial metabolite mimicry is a viable strategy for drug discovery and opens the door to mine underexploited regions of chemical space.
- organism: human
- assay: proteomics
- assay: metagenomics
- research focus: drug response / drug discovery
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In Vitro Safety Signals for Potential Clinical Development of the Anti-Inflammatory Pregnane X Receptor Agonist FKK6
Z. Dvorak, B. Vyhlidalov, … S. Mani·bioRxiv·Oct 21, 2023
- Unlocking the Potential: FKK6 as a Microbial Mimicry Based Therapy for Chronic Inflammation-Associated Colorectal Cancer in a Murine Model
Lucia Sládeková, Hao Li, … Zdeněk Dvořák·Journal of Pharmacology and Experimental TherapeuticsPeer-reviewed·Jul 30, 2024
- Chemoproteomics of microbiota metabolites reveals small-molecule agonists for orphan receptor GPRC5A
X. Zhao, K. R. Stein, … H. C. Hang·bioRxiv·Dec 16, 2021
- The gut microbiome shapes pharmacology and treatment outcomes for a key anti-inflammatory therapy
Vanya Sofia Villa Soto, Alexandra L. Degraeve, … Renuka R. Nayak·bioRxiv·Jun 26, 2025
- Targeting Pregnane X Receptor with a Potent Agonist-Based PROTAC to Delay Colon Cancer Relapse
Lucile Bansard, Guillaume Laconde, … Jean‐Marc Pascussi·OncogenesisPeer-reviewed·Aug 30, 2025
- Mapping interactions of microbial metabolites and human receptors
D. A. Colosimo, J. A. Kohn, … S. F. Brady·bioRxiv·May 3, 2019